RedHill’s Q219 results released on 23 July 2019 described steady progress across its pipeline, with TALICIA the centre of attention as the PDUFA date (2 November 2019) approaches. Based on the data released, we assign a high likelihood of FDA approval due to the clean dataset from the Phase III trials. From a commercial perspective, RedHill also appears to be ready with a US team in operation since mid-2017. Although potential approval and launch of TALICIA will dominate H219 newsflow,
30 Jul 2019
RedHill Biopharma - TALICIA will dominate newsflow in H219
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
RedHill Biopharma - TALICIA will dominate newsflow in H219
- Published:
30 Jul 2019 -
Author:
Dr Jonas Peciulis -
Pages:
5
RedHill’s Q219 results released on 23 July 2019 described steady progress across its pipeline, with TALICIA the centre of attention as the PDUFA date (2 November 2019) approaches. Based on the data released, we assign a high likelihood of FDA approval due to the clean dataset from the Phase III trials. From a commercial perspective, RedHill also appears to be ready with a US team in operation since mid-2017. Although potential approval and launch of TALICIA will dominate H219 newsflow,